Illumina ordered by EU antitrust regulators to sell Grail
Reuters
Published Oct 12, 2023 05:56AM ET
Updated Oct 12, 2023 06:07AM ET
By Foo Yun Chee
BRUSSELS (Reuters) - U.S. genetic testing company Illumina (NASDAQ:ILMN) has been ordered by EU antitrust regulators to sell cancer test maker Grail after it completed the deal before securing their approval.
Antitrust watchdogs on both sides of the Atlantic have sharpened their scrutiny of pharma and biotech deals in recent years on fears that some of these may stifle innovation and reduce competition in the sector.
The gun-jumping cost Illumina a record EU antitrust fine of 432 million euros ($457 million) for such an offence.
The EU competition enforcer subsequently blocked the $7.1 billion deal in 2022 on concerns that Illumina would have an incentive to stop Grail's rivals from accessing its technology to develop competing blood-based early cancer detection tests.
"With today's decision, the Commission has adopted restorative measures requiring Illumina to divest Grail and restore the situation prevailing before the completion of the acquisition," the European Commission said in a statement on Thursday, confirming a Reuters story.
The EU watchdog ordered Illumina to restore Grail's independence to the same level as prior to its acquisition and to ensure that it is as viable and competitive as before the takeover.
Illumina can choose to divest Grail via a trade sale, a capital markets transaction or other methods, but must do it within strict deadlines.
The company must keep Grail separate and viable until the sale is completed.
Illumina said that it was currently reviewing the divestment order.
The company has sued the EU watchdog for blocking the deal, its decision to examine the case despite not meeting the EU merger criteria, an order to keep Grail separate so that it can unwind the deal and the gun-jumping decision.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.